Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout paymentsApproximately $550 ...
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (LAB) (Standard BioTools or the Company), driven by a bold purpose – Unleashing tools to accelerate breakthroughs ...
Hosted on MSN
Standard BioTools outlines $165M-$175M revenue target for FY2025 while driving proteomics partnerships
CEO Michael Egholm highlighted that Standard BioTools delivered Q1 2025 revenues of $40.8 million, aligned with their plan despite a challenging operating backdrop. He emphasized improvements in ...
Standard BioTools, is engaged in product rationalization, cost-cutting and operational efficiency measures in an attempt to turn its business around and transition to profitability. The company’s ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results